Cosmo Pharmaceuticals N.V. (SWX:COPN)

Market Cap	1.40B +60.8%
Revenue (ttm)	96.99M -61.0%
Net Income	-3.36M
EPS	-0.21
Shares Out	16.19M
PE Ratio	n/a
Forward PE	936.72
Dividend	1.94 (2.24%)
Ex-Dividend Date	Apr 24, 2026

Volume	32,826
Average Volume	68,622
Open	86.40
Previous Close	86.40
Day's Range	84.10 - 87.10
52-Week Range	41.60 - 129.40
Beta	1.55
RSI	43.63
Earnings Date	Mar 9, 2026

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cor...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1997
• Employees: 325
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: COPN

Financial Performance

Financial numbers in EUR